Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to advancing treatment in multiple disease areas, including inflammatory and autoimmune diseases, genetic deficiencies and cancer. Unfortunately, unwanted immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rup, B, Pallardy, M, Sikkema, D, Albert, T, Allez, M, Broet, P, Carini, C, Creeke, P, Davidson, J, De Vries, N, Finco, D, Fogdell-Hahn, A, Havrdova, E, Hincelin-Mery, A, C Holland, M, H Jensen, P E, Jury, E C, Kirby, H, Kramer, D, Lacroix-Desmazes, S, Legrand, J, Maggi, E, Maillère, B, Mariette, X, Mauri, C, Mikol, V, Mulleman, D, Oldenburg, J, Paintaud, G, R Pedersen, C, Ruperto, N, Seitz, R, Spindeldreher, S, Deisenhammer, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557374/
https://www.ncbi.nlm.nih.gov/pubmed/25959571
http://dx.doi.org/10.1111/cei.12652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557374/
https://www.ncbi.nlm.nih.gov/pubmed/25959571
http://dx.doi.org/10.1111/cei.12652

Ejemplares similares